Jin Medical International Ltd.(ZJYL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $23.5M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ZJYL Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Jin Medical International Ltd. (ZJYL), a Healthcare sector company. ZJYL is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $23.5m in revenue. Based on the latest XBRL financial filings (FY 2025), Jin Medical International Ltd. reports quarterly revenue of $20.7M, net income of $1.2M, an operating margin of 2.9%. Top institutional holders of ZJYL by reported 13-F value include CITADEL ADVISORS, GEODE CAPITAL MANAGEMENT,, JANE STREET GROUP,, based on the most recent SEC filings. ZJYL trades on the Nasdaq exchange and files with the SEC under CIK 1837821. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZJYL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Jin Medical International Ltd. directly from SEC EDGAR.
Revenue
FY 2025
$20.7M
Net Income
FY 2025
$1.2M
Free Cash Flow
FY 2025
$-3.7M
Operating Margin
FY 2025
2.9%
ROIC
FY 2025
2.1%
D/E Ratio
FY 2025
0.64
Get alerted when ZJYL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Jin Medical International Ltd. including:
Top Institutional Holders of ZJYL
CITADEL ADVISORS LLC
$25.9K117,794 shGEODE CAPITAL MANAGEMENT, LLC
$23.4K106,540 shJANE STREET GROUP, LLC
$11.2K50,920 shRENAISSANCE TECHNOLOGIES LLC
$8.8K40,000 shOSAIC HOLDINGS, INC.
$7.0K32,000 shXTX Topco Ltd
$6.3K28,637 shTWO SIGMA SECURITIES, LLC
$4.8K21,971 shUBS Group AG
$987.004,486 shBell Investment Advisors, Inc
$34.00152 shMORGAN STANLEY
$22.00100 sh
| Fund | Value | Shares |
|---|---|---|
| CITADEL ADVISORS LLC | $25.9K | 117,794 |
| GEODE CAPITAL MANAGEMENT, LLC | $23.4K | 106,540 |
| JANE STREET GROUP, LLC | $11.2K | 50,920 |
| RENAISSANCE TECHNOLOGIES LLC | $8.8K | 40,000 |
| OSAIC HOLDINGS, INC. | $7.0K | 32,000 |
| XTX Topco Ltd | $6.3K | 28,637 |
| TWO SIGMA SECURITIES, LLC | $4.8K | 21,971 |
| UBS Group AG | $987.00 | 4,486 |
| Bell Investment Advisors, Inc | $34.00 | 152 |
| MORGAN STANLEY | $22.00 | 100 |
More Healthcare Companies
View all Healthcare →Put ZJYL on your watchlist
Track score changes the day Jin Medical International Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ZJYL a good stock to buy?
13F Pro's AI-powered analysis of Jin Medical International Ltd. (ZJYL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZJYL are available on the ZJYL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ZJYL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZJYL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Jin Medical International Ltd.'s investment landscape.